Product information and disease descriptionProduct descriptionProduct informationDosing and administration
Dosage
6 evidence topics · 5 sources
OptimUM-02 dose optimization arms and the selected combination dose in the registry record
OptimUM-02 randomized regimen: darovasertib 300 mg twice daily plus crizotinib 200 mg twice daily
OptimUM-01 first-line cohort: recommended phase 2 dose and delivered dose intensity
Crizotinib label: recommended dosage of 250 mg twice daily for adults with NSCLC
Crizotinib label: dose reduction levels for adults, with 200 mg twice daily as the first reduction
| Dose reduction level for adult patients with NSCLC or IMT | Dose and schedule |
|---|---|
| First dose reduction | “200 mg twice daily” |
| Second dose reduction | “250 mg once daily” |
Crizotinib label: dosage modification for hematologic toxicities in adults
| Severity of hematologic adverse reaction in adult patients with NSCLC or IMT | Dosage modification |
|---|---|
| Grade 3 | “Withhold until recovery to Grade 2 or less, then resume at the same dosage.” |
| Grade 4 | “Withhold until recovery to Grade 2 or less, then resume at next lower dosage.” |